ArticleJournal of separation science2026
Discovery of Cardioprotective Markers in Huangqi Shengmai Yin via Integrated UHPLC-Q-TOF-MS/MS Fingerprinting, Chemometric Quality Assessment, and Bioactivity Correlation.
Article in Journal of separation science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Huangqi Shengmai Yin (HQSMY) displays notable cardioprotective properties. Nevertheless, the principal pharmacodynamic constituents underpinning this efficacy have not yet been fully clarified. To tackle this issue, an integrative workflow coupling UHPLC‑Q‑TOF‑MS/MS fingerprinting, chemometrics, and spectrum‑effect correlations was constructed for the systematic discovery of cardioprotective markers. Fifty-one components from 10 batches of HQSMY samples were characterized by UHPLC‑Q‑TOF‑MS/MS in conjunction with the GNPS molecular networking platform. Subsequently, chromatographic fingerprints were established, with 22 and 29 characteristic common peaks assigned in negative and positive ion modes, respectively. Interbatch consistency was assessed via chemometric methods. Spectrum‑effect relationship analyses were conducted through Pearson correlation, gray relational analysis, and OPLS regression, revealing that formononetin, astrapterocarpan, astragaloside II, schisandrin, and biochanin A exhibited highly significant positive correlations with H9c2 cardiomyocyte protective activity. All these compounds attained gray relational scores exceeding 0.7, implying strong associations with cardioprotective action. These five components were then chosen from the candidate markers for subsequent functional validation using the CCK-8 assay, which yielded EC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.